Cover Image

Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab

Aim: To evaluate changes in health-related quality of life (HRQoL) in a Phase II trial (NCT02155647) of treatment-naive patients with metastatic Merkel cell carcinoma treated with avelumab (15-month follow-up). Materials & methods: Mixed-effect Models for Repeated Measures were applied to HRQoL...

Full description

Saved in:
Bibliographic Details
Main Authors: Bharmal, Murtuza (Author) , Nolte, Sandra (Author) , Lebbé, Céleste (Author) , Mortier, Laurent (Author) , Brohl, Andrew S (Author) , Fazio, Nicola (Author) , Grob, Jean-Jacquez (Author) , Pusceddu, Sara (Author) , Hanna, Glenn J (Author) , Hassel, Jessica C. (Author) , Kiecker, Felix (Author) , Ellers-Lenz, Barbara (Author) , Bajars, Marcis (Author) , Güzel, Gülseren (Author) , Nghiem, Paul (Author) , Hunger, Matthias (Author) , Schlichting, Michael (Author) , Henry-Szatkowski, Mickaël (Author) , D’Angelo, Sandra P. (Author)
Format: Article (Journal)
Language:English
Published: 2020
In: Future oncology
Year: 2020, Volume: 16, Issue: 27, Pages: 2089-2099
ISSN:1744-8301
DOI:10.2217/fon-2020-0426
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.2217/fon-2020-0426
Verlag, kostenfrei, Volltext: https://www.tandfonline.com/doi/full/10.2217/fon-2020-0426
Get full text
Author Notes:Murtuza Bharmal, Sandra Nolte, Céleste Lebbé, Laurent Mortier, Andrew S Brohl, Nicola Fazio, Jean-Jacquez Grob, Sara Pusceddu, Glenn J Hanna, Jessica C Hassel, Felix Kiecker, Barbara Ellers-Lenz, Marcis Bajars, Gülseren Güzel, Paul Nghiem, Matthias Hunger, Michael Schlichting, Mickaël Henry-Szatkowsk &, Sandra P. D’Angelo
Description
Summary:Aim: To evaluate changes in health-related quality of life (HRQoL) in a Phase II trial (NCT02155647) of treatment-naive patients with metastatic Merkel cell carcinoma treated with avelumab (15-month follow-up). Materials & methods: Mixed-effect Models for Repeated Measures were applied to HRQoL data (FACT-M; EQ-5D-5L) to assess changes over time. Clinically derived progression-free survival was compared with HRQoL deterioration-free survival. Results: Overall, we saw relative stability in HRQoL among 116 included patients, with nonprogression associated with statistically and clinically meaningful better HRQoL compared with progressive disease. Deterioration-free survival rates (49-72% at 6 months, 40-58% at 12 months) were consistently higher/better compared with progression-free survival rates (41/31% at 6/12 months). Conclusion: These findings show unique longitudinal HRQoL data for treatment-naive metastatic Merkel cell carcinoma patients treated with avelumab. Clinical trial registration: NCT02155647 (ClinicalTrials.gov). Infographic: A PDF version of this infographic is available as supplemental material.
Item Description:Gesehen am 25.09.2025
Physical Description:Online Resource
ISSN:1744-8301
DOI:10.2217/fon-2020-0426

Similar Items